Becanex Acquires Bedrocan Brand and Canadian Unit
BERLIN – Becanex, a EU-GMP-certified medical Cannabis extraction company, has acquired the shares of Bedrocan Canada, international trademarks, web domains, and Canadian subsidiary of the insolvent Dutch producer Bedrocan for €200,000. Executed through the Dutch holding entity Kamphorst Agrofonds 3 B.V., the deal transfers the names of the Bedrocan strains and full ownership of Bedrocan Canada Ltd., which operates an indoor cultivation facility in Toronto licensed by Health Canada.
The sale follows the bankruptcy ruling by the District Court of Northern Netherlands against Bedrocan Nederland B.V. and Bedrocan International B.V., which left the Dutch medical Cannabis program without an active domestic grower. Bedrocan entered insolvency after its exclusive supply contract with the Dutch Office of Medicinal Cannabis expired at the beginning of 2026 and state authorities declined to place interim orders ahead of planned regulatory reforms. Court appointed trustees dismissed all 69 employees at the Dutch site the day after the ruling, while recording €20.5 million in 2025 revenue alongside €14.32 million in combined bank and lender claims. Since Bedrocan Canada Ltd. remained financially solvent despite belonging to the broader corporate estate, trustees separated the Canadian subsidiary and intellectual property for a standalone sale.
Becanex Managing Director Sebastian Kamphorst stated that Bedrocan established the European benchmark for standardized medical Cannabis and noted that the acquisition preserves decades of selective breeding alongside the brand name. The two companies had already formed a commercial partnership in May 2026 to formulate standardized Cannabis extracts in Berlin from Bedrocan flower for German pharmacies. Under the revised structure, the sons of Bedrocan founder Jaap Erkelens will manage plant cultivation at the Toronto facility under a lease arrangement with Becanex, while Becanex oversees pharmaceutical extraction in Germany.
Commercial output from the Toronto site will require regulatory clearance and is not expected to reach patients before H2 2027, including low THC formulations like Bedrolite®. In the meantime, the Dutch government plans to halt official medical Cannabis exports at the end of 2026 and launch a European tender in December to secure interim imported supplies for roughly 7,000 domestic patients. The Dutch health minister wrote to parliament on November 6 that no extra Bedrolite is available for export after weak harvests. Her letter points to Bedrobinol® stock running out in early Q2 2027 and Bedrolite in early third quarter, while a new Dutch supplier is due to start in September 2027.
Separately, the Erkelens family has submitted a bid to revive domestic Dutch operations under a new legal entity, a proposal still awaiting approval from a bankruptcy judge.
The price is modest, but the assets are the parts of Bedrocan that prescribers recognize by name. A brand and a full set of genetics are hard to rebuild, and one extract maker in Berlin now controls both. The open question is timing. Canadian flower still needs regulatory approval before it reaches European pharmacies, and on the minister’s own schedule, Dutch stocks of both varieties run out before replacement supply begins. Becanex also takes on a facility it plans to expand, which costs money and time. For investors and partners watching European medical cannabis, the sale shows how a bankruptcy can split one company into pieces with different owners. Patients with few alternatives, especially those using Bedrolite, will judge the outcome by supply rather than ownership.






































